Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Fri, 11.02.2022
Saturn Oil & Gas Inc.
Upcoming Investor Event:
Saturn Oil + Gas to present at digital International Investment Forum (IIF)
On February 17, the IIF International Investment Forum will take place. At
this forum, Saturn Oil + Gas will also present its business model and
current business development.
Presentation slot:
Saturn Oil + Gas Inc. (ISIN: CA80412L8832)
11.15 [ … ]
Thu, 10.02.2022
Advanced Blockchain AG
Advanced Blockchain AG is a venture builder and investor in the blockchain
ecosystem equipped with a comprehensive team of researchers, developers,
auditors, economists, and mathematicians dedicated to engineering the
future of Web 3.0.
GBC AG: Hello Mr. Geike, can you give me a quick rundown of your company,
your business model, and your strate [ … ]
Thu, 10.02.2022
Cardiol Therapeutics Inc.
Upcoming Investor Event:
Cardiol Therapeutics to present at digital International Investment Forum
(IIF)
On February 17, the IIF International Investment Forum will take place. At
this forum, Cardiol Therapeutics will also present its business model and
current business development.
Presentation slot:
Cardiol Therapeutics Inc. (ISIN: CA14161Y2 [ … ]
Thu, 10.02.2022
Defence Therapeutics Inc.
Uniquely Positioned with versatile ACCUM(TM); Enormous upside potential;
Next generation of cancer treatment
- Proprietary platform technology with proven enhanced intracellular
delivery. Promotes delivery of target product without non-specific
protein/antigen degradation or interference.
- Strong versatility of the Accum(TM) platf [ … ]
Wed, 09.02.2022
MagForce AG
In the past fiscal year 2021, MagForce AG made progress in both business
segments. Of particular note here is the approval granted by the FDA for
the start of Stage 2b for the treatment of prostate cancer patients. This
means that the pivotal study could be concluded as early as summer 2022. In
parallel, the treatment capacities for the indication [ … ]
Wed, 02.02.2022
Saturn Oil & Gas Inc.
Oxbow facilities
We had the chance to visit the newly acquired Oxbow Asset in September
2021. The site visit included a complete tour and presentation of new
management as well as a trip to production assets, pads, facilities and an
introduction to many employees and contractual companies. The assets
visited were located in a fairly concentrated [ … ]
Wed, 02.02.2022
Cogia AG
Preliminary results significantly above forecast, price target confirmed
On January 21, 2022, Cogia AG published its preliminary figures for the
2021 financial year and the figures presented exceed the GBC analysts'
forecasts. A total output of EUR 1.7 million was achieved in the group,
which corresponds to almost a threefold increase (previous [ … ]
Fri, 28.01.2022
HAEMATO AG
PCR PoC-Device added to the product portfolio; revenue and earnings
forecasts unchanged, upside potential anticipated from new products, price
target and BUY rating confirmed
In our last management interview (http://www.more-ir.de/d/23165.pdf) on the
current developments of HAEMATO AG, the CEO Patrick Brenske had announced
the addition of a mobi [ … ]
Mon, 24.01.2022
Defence Therapeutics Inc.
GBC Research Watchlist: Defence Therapeutics
Defence Therapeutics is led by Sebastien Plouffe. Mr. Plouffe has been a
successful Investment Advisor and CEO notably in the resource sector,
leading several junior companies to profitable exits. Mr. Plouffe is
supported by Dr. Moutih Rafei, VP R&D and Dr. Simon Beaudoin CTSO. Dr.
Rafei is a worl [ … ]
Wed, 19.01.2022
The NAGA Group AG
Strong revenue and earnings growth in 2021; guidance for 2022 significantly
above our expectations; estimates and share price target raised
According to preliminary figures for the past financial year 2021, The NAGA
Group AG (short to: NAGA) achieved significant revenue growth as expected.
Compared to the previous year, consolidated sales more t [ … ]